CFO4Life Group LLC Takes Position in Cencora, Inc. (NYSE:COR)

CFO4Life Group LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 1,185 shares of the company’s stock, valued at approximately $288,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. bought a new position in Cencora during the fourth quarter worth $4,212,508,000. Bank of New York Mellon Corp bought a new position in Cencora during the first quarter worth $291,825,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Cencora during the first quarter worth $238,457,000. Mawer Investment Management Ltd. acquired a new stake in Cencora in the first quarter worth $191,309,000. Finally, Principal Financial Group Inc. acquired a new stake in Cencora in the first quarter worth $75,916,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Trading Up 0.4 %

Shares of NYSE:COR traded up $0.96 during midday trading on Friday, reaching $222.96. The company had a trading volume of 361,881 shares, compared to its average volume of 1,374,345. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. Cencora, Inc. has a 1-year low of $171.65 and a 1-year high of $246.75. The firm has a market cap of $44.47 billion, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45. The company has a fifty day simple moving average of $226.68 and a two-hundred day simple moving average of $229.13.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The business had revenue of $68.41 billion during the quarter, compared to analyst estimates of $70.60 billion. During the same quarter last year, the company posted $3.50 EPS. Cencora’s revenue for the quarter was up 7.8% on a year-over-year basis. Research analysts predict that Cencora, Inc. will post 13.46 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were given a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.91%. Cencora’s payout ratio is presently 22.32%.

Analysts Set New Price Targets

COR has been the topic of several analyst reports. Robert W. Baird increased their target price on Cencora from $280.00 to $285.00 and gave the stock an “outperform” rating in a research report on Tuesday. Citigroup raised their price target on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. SVB Leerink reissued an “outperform” rating and set a $275.00 price target on shares of Cencora in a report on Thursday, June 27th. Finally, StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.10.

Insiders Place Their Bets

In other news, Director Dermot Mark Durcan purchased 500 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was bought at an average cost of $218.58 per share, with a total value of $109,290.00. Following the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at $4,781,656.08. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Dermot Mark Durcan purchased 500 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was bought at an average cost of $218.58 per share, with a total value of $109,290.00. Following the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at $4,781,656.08. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Steven H. Collis sold 10,754 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,956,675 shares of company stock worth $422,352,056. 15.80% of the stock is currently owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.